{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:35:50Z","timestamp":1790786150601,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Kosegarten Family Research Fund"},{"name":"Stoltz Family Research Fund"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ygyno.2020.02.008","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T23:10:14Z","timestamp":1582067414000},"page":"348-356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia\/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates"],"prefix":"10.1016","volume":"157","author":[{"given":"Stefany","family":"Acosta-Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2855-0867","authenticated-orcid":false,"given":"Tricia","family":"Murdock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayna","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Beavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Wethington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Levinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Grumbine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Stuart","family":"Ferriss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda N.","family":"Fader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ygyno.2020.02.008_bb0005","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jnci\/djx214","article-title":"International patterns and trends in endometrial cancer incidence, 1978\u20132013","volume":"110","author":"Lortet-Tieulent","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.ygyno.2020.02.008_bb0010","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2012.01.003","article-title":"Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review","volume":"125","author":"Gunderson","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.02.008_bb0015","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.fertnstert.2013.11.028","article-title":"Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis","volume":"101","author":"Koskas","year":"2014","journal-title":"Fertil. Steril."},{"issue":"2","key":"10.1016\/j.ygyno.2020.02.008_bb0020","doi-asserted-by":"crossref","first-page":"170","DOI":"10.6004\/jnccn.2018.0006","article-title":"Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology","volume":"16","author":"Koh","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.008_bb0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.008_bb0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2004.06.045","article-title":"Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review","volume":"95","author":"Ramirez","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2020.02.008_bb0035","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/1471-0528.12499","article-title":"Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial","volume":"121","author":"Orbo","year":"2014","journal-title":"BJOG"},{"issue":"1","key":"10.1016\/j.ygyno.2020.02.008_bb0040","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ygyno.2009.09.024","article-title":"Metformin is a potent inhibitor of endometrial cancer cell proliferation\u2014implications for a novel treatment strategy","volume":"116","author":"Cantrell","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"3\u20135","key":"10.1016\/j.ygyno.2020.02.008_bb0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jsbmb.2010.12.006","article-title":"Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells","volume":"126","author":"Xie","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.02.008_bb0050","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/annonc\/mdv539","article-title":"Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer","volume":"27","author":"Mitsuhashi","year":"2016","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2020.02.008_bb0055","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.3802\/jgo.2019.30.e90","article-title":"Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients","volume":"30","author":"Mitsuhashi","year":"2019","journal-title":"J. Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.02.008_bb0060","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3802\/jgo.2014.25.3.214","article-title":"Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia","volume":"25","author":"Shan","year":"2014","journal-title":"J. Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2020.02.008_bb0065","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00000478-198307080-00012","article-title":"Endometrial hyperplasia and carcinoma: diagnostic considerations*","volume":"7","author":"Norris","year":"1983","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.02.008_bb0070","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7150\/jca.8009","article-title":"Combination of Diane-35 and metformin to treat early endometrial carcinoma in PCOS women with insulin resistance","volume":"5","author":"Li","year":"2014","journal-title":"J. Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2020.02.008_bb0075","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1471-0528.2010.02552.x","article-title":"Progestogen treatment options for early endometrial cancer","volume":"117","author":"Cade","year":"2010","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.02.008_bb0080","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/IGC.0b013e31819c5372","article-title":"Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients","volume":"19","author":"Eftekhar","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.02.008_bb0085","author":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"},{"issue":"6","key":"10.1016\/j.ygyno.2020.02.008_bb0090","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1097\/AOG.0b013e31828d6186","article-title":"Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma","volume":"121","author":"Hubbs","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.02.008_bb0095","author":"ClinicalTrial.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"},{"key":"10.1016\/j.ygyno.2020.02.008_bb0100","author":"ClinicalTrial.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"},{"key":"10.1016\/j.ygyno.2020.02.008_bb0105","author":"ClinicalTrial.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820301037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820301037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:48:40Z","timestamp":1758772120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820301037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0090825820301037"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.02.008","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia\/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}